WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer will present detailed results from the Phase III FIDELIO-DKD study assessing the use of the investigational drug finerenone on kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) during scientific sessions of the upcoming American Society of Nephrology’s (ASN) Kidney Week, October 22-25, 2020. Additional data evaluating use of finerenone will also be presented.
The FIDELIO-DKD study, which evaluated the efficacy and safety of finerenone versus placebo when added to standard of care in patients with CKD and T2D, is the first large contemporary positive outcomes study in patients with CKD and T2D with a primary composite endpoint exclusively consisting of kidney-specific outcomes. Bayer announced earlier this year that FIDELIO-DKD met its composite primary renal endpoint and its composite key secondary cardiovascular endpoint.
Full data from the FIDELIO-DKD study will be presented as part of the live-streamed, late-breaker
This third article in this series about being politically savvy in the workplace builds upon the foundational insights of the prior two articles.
Office Politics I addressed the issue of neutralizing a toxic person at your workplace instead of committing either of the two fatal errors of trying to make them a friend or treating them like an enemy. Instead, we want to neutralize their toxic effect upon the work environment.
Office Politics II showed you how to use public displays of camaraderie to neutralize “behind your back” toxic communications.
This article looks at another technique for neutralizing a dangerous colleague in the workplace.
Judo and Karate
I’m not very good at either but have had lessons and advanced a ways into the rainbow of belts in both judo and karate. I know enough to really make a dangerous opponent even madder at me than they were before. But I … Read More